Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride -

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - olsalazine sodium - oral capsule - 250mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - olsalazine sodium - oral tablet - 500mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - olsalazine sodium - oral capsule - 250mg

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - olsalazine sodium - capsule, hard - 250 milligram(s) - aminosalicylic acid and similar agents; olsalazine

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

atnahs pharma netherlands b.v. - olsalazine sodium - tablet - 500 milligram(s) - aminosalicylic acid and similar agents; olsalazine

Marekani - Kiingereza - NLM (National Library of Medicine)

american regent, inc. - polysulfated glycosaminoglycan (unii: 268aw7000t) (polysulfated glycosaminoglycan - unii:268aw7000t) - adequan® canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. do not use in dogs showing hypersensitivity to psgag. psgag is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders.

Israeli - Kiingereza - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 10000 iu/ml - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - mucopolysaccharide polysulfate 0,3 g/100 g - cream - 300 mg/100 g - mucopolysaccharide polysulfate 3 mg/g - organo-heparinoid